Caris Life Sciences Inc. Common Stock (CAI)

FairStock Score: 27/100 — RISKY

Key Financials

Strengths

• Generates $102 million in annual free cash flow (1.8% yield on market cap)
• High return on equity of 28.4% demonstrating efficient capital deployment
• Altman Z-Score of 4.4 confirms minimal bankruptcy risk and strong solvency

AI Analysis

Caris Life Sciences Inc. Common Stock is a small-cap healthcare company valued at $5.6 billion. The business generates $907 million in annual revenue with a 9.0% net margin and $102 million in free cash flow. From a quality standpoint, Caris shows solid Piotroski F-Score of 6/9 and healthy Altman Z-Score of 4.4. On valuation, the stock is 0.7% FCF yield. Our composite FairStock Score of 27/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $102 million in annual free cash flow (1.8% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer